- Home
- GMAB vs JKHY Comparison
GMAB vs JKHY Comparison
Compare GMAB & JKHY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMAB
- JKHY
- Stock Information
- Founded
- GMAB 1999
- JKHY 1976
- Country
- GMAB Denmark
- JKHY United States
- Employees
- GMAB N/A
- JKHY N/A
- Industry
- GMAB Biotechnology: Pharmaceutical Preparations
- JKHY Retail: Computer Software & Peripheral Equipment
- Sector
- GMAB Health Care
- JKHY Technology
- Exchange
- GMAB Nasdaq
- JKHY Nasdaq
- Market Cap
- GMAB 12.1B
- JKHY 12.1B
- IPO Year
- GMAB N/A
- JKHY N/A
- Fundamental
- Price
- GMAB $24.14
- JKHY $191.28
- Analyst Decision
- GMAB Buy
- JKHY Hold
- Analyst Count
- GMAB 9
- JKHY 11
- Target Price
- GMAB $40.71
- JKHY $186.80
- AVG Volume (30 Days)
- GMAB 1.2M
- JKHY 654.7K
- Earning Date
- GMAB 05-01-2025
- JKHY 02-04-2025
- Dividend Yield
- GMAB N/A
- JKHY 1.21%
- EPS Growth
- GMAB 83.82
- JKHY 8.62
- EPS
- GMAB 16.85
- JKHY 5.55
- Revenue
- GMAB $2,988,286,182.00
- JKHY $2,273,303,000.00
- Revenue This Year
- GMAB $19.59
- JKHY $9.23
- Revenue Next Year
- GMAB $14.50
- JKHY $7.23
- P/E Ratio
- GMAB $14.08
- JKHY $34.46
- Revenue Growth
- GMAB 30.67
- JKHY 5.23
- 52 Week Low
- GMAB $18.64
- JKHY $157.00
- 52 Week High
- GMAB $31.88
- JKHY $193.02
- Technical
- Relative Strength Index (RSI)
- GMAB 71.05
- JKHY 77.92
- Support Level
- GMAB $23.63
- JKHY $175.34
- Resistance Level
- GMAB $24.11
- JKHY $183.33
- Average True Range (ATR)
- GMAB 0.37
- JKHY 4.37
- MACD
- GMAB 0.22
- JKHY 1.98
- Stochastic Oscillator
- GMAB 93.88
- JKHY 93.96
About GMAB Genmab A/S ADS
Genmab AS is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About JKHY Jack Henry & Associates Inc.
Jack Henry is a leading provider of core processing and complementary services, such as electronic funds transfer, payment processing, and loan processing for us banks and credit unions, with a focus on small and midsize banks. Jack Henry serves almost 1,000 banks and over 700 credit unions.